Bone-derived CAFs express CXCL12 which directly stimulates the CXCR4 receptor on the surface of prostate cancer cells to elicit a protective effect from chemotherapy, as well as promoting metastatic progression and attracting inflammatory immune cells to the TME [284,289]. Here, CXCL12 is linked to prostate cancer.